|
THAP5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.21724893790088E-15 |
| Normal-vs-Stage2 |
2.785700E-04 |
| Normal-vs-Stage3 |
7.01660951563099E-14 |
| Normal-vs-Stage4 |
2.1218582446636E-12 |
| Stage1-vs-Stage2 |
8.499700E-02 |
| Stage1-vs-Stage3 |
1.006380E-01 |
| Stage1-vs-Stage4 |
8.297000E-03 |
| Stage2-vs-Stage3 |
1.278420E-02 |
| Stage2-vs-Stage4 |
1.283970E-03 |
| Stage3-vs-Stage4 |
2.086400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
1.177280E-04 |
| Normal-vs-Asian |
5.81960035717088E-11 |
| Caucasian-vs-AfricanAmerican |
3.331000E-01 |
| Caucasian-vs-Asian |
6.560200E-01 |
| AfricanAmerican-vs-Asian |
3.133000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.99680288865056E-15 |
| Normal-vs-Female |
1.66611169305497E-12 |
| Male-vs-Female |
8.886000E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.86317627992594E-12 |
| Normal-vs-Age(41-60Yrs) |
1.73305814143987E-13 |
| Normal-vs-Age(61-80Yrs) |
1.26819998946814E-10 |
| Normal-vs-Age(81-100Yrs) |
2.377100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.417600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.765800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.795000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.613400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.665200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.790400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.038160E-04 |
| Classical-VS-Follicular |
1.552420E-02 |
| Classical-VS-Other |
2.968800E-01 |
| Classical-VS-Normal |
1.55619961361708E-10 |
| Tall-VS-Follicular |
8.50429999976754E-07 |
| Tall-VS-Other |
5.726400E-01 |
| Tall-VS-Normal |
1.64135371960583E-12 |
| Follicular-VS-Other |
1.222240E-01 |
| Follicular-VS-Normal |
3.61950000000721E-05 |
| Other-VS-Normal |
4.824500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.42650011195167E-10 |
| Normal-vs-N1 |
1.82853732155763E-13 |
| N0-vs-N1 |
8.598400E-04 |
|
|
